AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

GlycoMimetics to Present at Two Upcoming Investor Conferences

November 13, 2019 GMT

ROCKVILLE, Md.--(BUSINESS WIRE)--Nov 13, 2019--

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that company executives will provide a corporate update at two upcoming investor relations conferences in November. Details are as follows:

STIFEL HEALTHCARE CONFERENCE (NEW YORK)
Date: Tuesday, November 19, 2019
Time: 4:10 p.m. ET
Presenter: GlycoMimetics CFO Brian Hahn

JEFFERIES 2019 LONDON Healthcare Conference
Date: Thursday, November 21, 2019
Time: 7:20 a.m. GMT
Presenter: GlycoMimetics CEO Rachel King

To access the live webcast and subsequent archived recordings for this presentation, please visit the GlycoMimetics website at www.glycomimetics.com.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics’ wholly-owned drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including a Company-sponsored Phase 3 trial in relapsed/refractory AML. GlycoMimetics has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191113005042/en/

CONTACT: Investor Contact:

Shari Annes

Phone: 650-888-0902

Email:sannes@annesassociates.comMedia Contact:

Jamie Lacey-Moreira

Phone: 410-299-3310

Email:jamielacey@presscommpr.com

KEYWORD: NEW YORK MARYLAND EUROPE UNITED STATES UNITED KINGDOM NORTH AMERICA

INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES OTHER SCIENCE CLINICAL TRIALS SCIENCE PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: GlycoMimetics, Inc.

Copyright Business Wire 2019.

PUB: 11/13/2019 09:00 AM/DISC: 11/13/2019 09:00 AM

http://www.businesswire.com/news/home/20191113005042/en